Question

What is true about leukemia and Down syndrome?

• A. AML in Down syndrome has a better prognosis than AML in the general population, and the most common tumor in $<$ 3 years of age is ALL.
• B. ALL in Down syndrome has a better prognosis than ALL in the general population, and the most common tumor in $<$ 3 years of age is AML.
• C. AML in Down syndrome has a worse prognosis than AML in the general population, and the most common tumor in $<$ 3 years of age is ALL.
• D. ALL in Down syndrome has a worse prognosis than ALL in the general population, and the most common tumor in $<$ 3 years of age is AML.

Hint:

Down Syndrome Leukemia High-Yield Rules:
- Age $< 3$ years: AML (M7 Megakaryoblastic) is most common $\rightarrow$ Highly curable Excellent prognosis (GATA1 mutation, Cytarabine sensitive).
- Age $> 3$ years: ALL is most common $\rightarrow$ Worse prognosis and increased chemotherapy toxicity compared to general population.

Answer 1

The Correct Option is D

Concept:
Children with Down syndrome (Trisomy 21) have a 10- to 20-fold increased risk of developing childhood acute leukemias compared to the general pediatric population.
The biological behavior, age distribution, and chemotherapy response of leukemias in Down syndrome differ markedly from non-Down syndrome patients.
Explanation:
• In children with Down syndrome younger than 3 years of age ($< 3\text{ years}$), Acute Myeloid Leukemia (specifically Acute Megakaryoblastic Leukemia - AMkL AML-M7 associated with somatic GATA1 mutations) is the predominant leukemia.

• AML in Down syndrome infants (Myeloid Leukemia of Down Syndrome - ML-DS) has an extraordinarily favorable event-free and overall survival ($> 80\text{--}90\%$) because trisomy 21 blasts have marked sensitivity to Cytarabine.

• In children with Down syndrome older than 3 years of age ($> 3\text{ years}$), Acute Lymphoblastic Leukemia (B-ALL) becomes the dominant subtype.

• In contrast to AML, ALL in children with Down syndrome is associated with an inferior (worse) prognosis and higher relapse rates compared to non-Down syndrome ALL patients.

• Furthermore, children with Down syndrome experience significantly heightened treatment-related toxicities (severe mucositis, cardiotoxicity, infectious mortality) from standard ALL chemotherapeutic agents (especially high-dose Methotrexate and Anthracyclines) due to altered pharmacokinetics and baseline immune dysregulation.
Final Answer:
In Down syndrome, AML is the most common leukemia in children younger than 3 years, and ALL in Down syndrome carries a worse prognosis with higher toxicity compared to ALL in the general population.